KalVista Pharmaceuticals Inc (KALV) concluded trading on Thursday at a closing price of $14.76, with 7.19 million shares of worth about $106.11 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 36.92% during that period and on Thursday the price saw a gain of about 2.50%. Currently the company’s common shares owned by public are about 34.17M shares, out of which, 19.09M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 33 times over the past 12 months. They bought 187,867 shares in 16 of the transactions. In 17 selling transactions, insiders dumped 110,936 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stock saw a price change of -0.94% in past 5 days and over the past one month there was a price change of 13.54%. Year-to-date (YTD), KALV shares are showing a performance of 20.49% which increased to 86.13% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.26 but also hit the highest price of $16.88 during that period. The average intraday trading volume for KalVista Pharmaceuticals Inc shares is 495.21K. The stock is currently trading 3.24% above its 20-day simple moving average (SMA20), while that difference is up 18.82% for SMA50 and it goes to 43.44% higher than SMA200.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) currently have 34.17M outstanding shares and institutions hold larger chunk of about 67.38% of that.
The stock has a current market capitalization of $510.11M and its 3Y-monthly beta is at 0.93. It has posted earnings per share of -$3.05 in the same period. It has Quick Ratio of 7.25 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KALV, volatility over the week remained 10.58% while standing at 7.59% over the month.
Analysts are in expectations that KalVista Pharmaceuticals Inc (KALV) stock would likely to be making an EPS of -$0.77 in the current quarter, while forecast for next quarter EPS is -$0.76 and it is -$2.7 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.89 which is -$0.69 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.75 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 8.16% while it is estimated to increase by 11.72% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on June 15, 2020 offering a Buy rating for the stock and assigned a target price of $30 to it.
